TinyGemsBreaks Archive - Page 113 of 139

WednesdayOct 19, 2022 12:16 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Receives Approval to Move Forward with ELSM Acquisition

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has received approval from the U.S. Bankruptcy Court to move forward on its acquisition of Electric Last Mile Solutions (“ELMS”) assets; ELSM is an electric vehicle company. According to the announcement, the Chapter 7-approved transaction paves the way for Mullen to acquire ELMS’s manufacturing plant along with all inventory and intellectual property. The acquisition will be an all-cash purchase; the company’s cash on hand and a funding commitment of up to $240 million provides the funds to finalize the acquisition and move forward with vehicle launches. The company noted that…

TuesdayOct 18, 2022 2:09 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Innovative Robot Roadshow Makes Stop in Dallas

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), and its Robot Roadshow are spending the day in Dallas. The roadshow is a free, engaging experiential event that is designed to provide potential clients, media and investors with an opportunity to see Knightscope’s game-changing security robots up close and personal. The stop in Dallas is at the Commemorative Air Force location from 10 a.m. to 3 p.m. CT. Knightscope is committed to share its offerings through creative marketing events, and the roadshow is an ideal example of this. So far, the event has landed in 64 different locations…

TuesdayOct 18, 2022 1:34 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Schedules Release of Q3 2022 Results, Conference Call

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, has announced that it will provide a business update and release its financial results for the third quarter of 2022 following the close of the market on Tuesday, Nov. 8, 2022. In addition, Cepton will hold a conference call and webcast at 2:30 p.m. PT (5:30 p.m. ET) that same day. Interested parties may join the call by dialing 888-999-6281 and visiting https://ibn.fm/01a5B for the live webcast. A replay will be available approximately two hours after the live call and until Nov. 22, 2022, and can be…

TuesdayOct 18, 2022 12:59 pm

TinyGemsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extend Research Pact

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an agreement with Columbia University to extend its current research partnership efforts. The agreement outlines certain assets that are currently under development regarding the work of associate professor of clinical Neurobiology Dr. Christine Ann Denny at Columbia University Irving Medical Center. Denny and her team are studying the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer’s disease. According to the announcement, Denny’s pioneering research is evaluating whether ketamine and novel inventions associated with the substance have potential…

MondayOct 17, 2022 1:36 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration…

MondayOct 17, 2022 1:06 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s original developer over 15 years ago. In its annual stockholder meeting, the company also provided an update for its secondary drug portfolio WP1244. The anthracycline-based substance, being evaluated for the treatment of brain cancers, ovarian and lymphomas, “has produced a new derivative as WP1874 with…

MondayOct 17, 2022 11:24 am

TinyGemsBreaks — Cepton Technologies Inc. (NASDAQ: CPTN) Partners with LidarSwiss to Create Nano P60 System

Cepton Technologies (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, announced that LidarSwiss Solutions GmbH is deploying its Sora(TM) lidar technology in the company’s drone-based mapping and analytics solution, which is available for infrastructure management and engineering design applications. The full Nano P60 system is on display at the INTERGEO event, held Oct. 18–20, 2022, in Germany. Based in Switzerland, LidarSwiss provides high-performance unmanned aerial vehicle (“UAV”)-based lidar solutions that feature high-fidelity mapping and real-time processing, a key solution for engineers, forestry managers and urban planners. The Nano P60 platform has been used to map and analyze…

MondayOct 17, 2022 9:30 am

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Continues to Broaden Reach with Fr8App B2B Marketplace

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an over-the-road shipping technology innovator, has developed an AI-powered marketplace solution for optimizing and automating the supply chain process to help keep trucks moving with minimal obstacles. “The company’s Fr8App B2B marketplace is its flagship product in a suite powered by AI and machine learning technology that helps connect shippers with qualified carriers as a real-time broker portal… In the company’s Q2 2022 financial report, Fr8Tech noted that quarterly revenue for the period ended June 30 grew 60% over the Q1 report and was up 45% for the period YoY, establishing a new record for…

FridayOct 14, 2022 12:29 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Marks Milestone Toward Unique and Uncompromising EV Experience

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, recently announced a partnership with Watergen Inc., an Israel-based company building technology and equipment that create drinking water from the air, to develop and equip Mullen’s portfolio of EVs with technology that will produce fresh drinking water for in-vehicle consumer and commercial application. “Watergen’s technology of ‘air to clean drinking water’ for vehicles can generate a fresh supply of hot and drinking water for vehicle occupants. This technology is envisioned for Mullen’s fleet of EV cargo vans and can be utilized in both commercial and recreational vehicle settings. The air-to-water…

FridayOct 14, 2022 12:05 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently released its financial results for the second quarter of the fiscal year ended June 30, 2022. “CNS kicked off Q3 2022 with approximately $9 million in cash, and working capital of approximately $10.3 million, which, it is confident, will fund its operations into the 2023 calendar year. Currently, the company is exploring the full potential of its lead product candidate, Berubicin. Results from clinical studies over the last six months have proven fruitful,…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks